Proteins from molecule to market
Novo Nordisk is a focused healthcare company that specialises in developing proteins from molecule to market. For nearly a century, we have been refining our protein competencies and establishing world-class expertise in:
- Protein engineering using mutation, pegylation and acylation, as well as genetic, enzymatic and chemical modification to engineer safe, effective and convenient therapeutic proteins for diabetes and other chronic conditions.
- Protein expression in E.coli, yeast, and mammalian cells. Novo Nordisk has state-of-the-art facilities with capacities up to 160,000 L, including commercial scale production of mammalian cells.
- Protein formulation is a key factor in optimising the interface between the complex protein molecule and its delivery system. Novo Nordisk continues to refine its protein formulation technology and masters half-life extension, sustained release, and liquid formulations. In addition, Novo Nordisk seeks partnerships to turn our injectable therapeutic proteins into tablet-based treatments.
- Protein delivery systems innovation was pioneered by Novo Nordisk with the introduction of the NovoPen® insulin pen device in 1985. Since then Novo Nordisk has developed more than 20 injection systems, including durable, pre-filled and cartridge devices.
We are committed to engineering proteins into safe and effective therapies and also developing new and improved protein delivery systems for the people who depend on our products. We recognise the need to match better treatment options with effective and convenient drug delivery systems that make it easier for people to adhere to treatment and achieve better outcomes.